The Anti-CD20 Reference Antibody (TRU-015) is utilized as a research and development tool for immune-related disorders, particularly those involving B cells, such as rheumatoid arthritis, leukemia, and autoimmune vasculitis. This antibody targets the CD20 antigen on the surface of B cells, facilitating the destruction or inhibition of aberrant B cells that drive inflammation and tissue damage.

In research applications, it serves as a reference standard for evaluating the performance of novel anti-CD20 antibodies, including binding affinity to CD20 protein on B cell surfaces and cytotoxicity against target cells. It is also employed in developing diagnostic assays, such as quantifying B cell levels in blood samples or assessing therapeutic responses in patients treated with anti-CD20 antibodies.

Mechanistically, it depletes B cells via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis induction. Originally investigated for conditions like non-Hodgkin’s lymphoma and rheumatoid arthritis, it provides a targeted strategy to reduce pathogenic B cells while preserving stem cells and plasma cells. Its humanized structure enhances tolerability and minimizes immunogenicity in experimental and therapeutic contexts.